Barclays analyst Matt Miksic reinstated coverage of Becton Dickinson (BDX) with an Overweight rating and $202 price target after the company sold its LifeSciences Bioprocessing segment for Waters.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target lowered to $170 from $205 at Piper Sandler
- Becton Dickinson price target lowered to $232 from $233 at Citi
- Becton, Dickinson Earnings Call: Growth Amid Tariff Drag
- BD Completes Biosciences Spin-Off and Waters Combination
- Options Volatility and Implied Earnings Moves Today, February 09, 2026